Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 12/20 | 0.58 |
| ▸ | TLR7 | Q9NYK1 | 8/20 | 0.50 |
| ▸ | HPGD | P15428 | 6/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | BCR | P11274 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10325503 | 0.89 | TLR8 (0.56) | TLR8TLR7HPGDMAPK1KDM4E | |
| SCHEMBL10325097 | 0.89 | TLR8 (0.63) | TLR8TLR7HPGDKDM4E | |
| SCHEMBL10325898 | 0.88 | TLR8 (0.57) | TLR8TLR7HPGDMAPK1ALDH1A1 | |
| SCHEMBL19265488 | 0.88 | TLR8 (0.58) | TLR8TLR7HPGDMAPK1ALDH1A1 | |
| SCHEMBL10325171 | 0.87 | TLR8 (0.60) | TLR8TLR7HPGDMAPK1ALDH1A1 | |
| SCHEMBL15499091 | 0.87 | TLR8 (0.58) | TLR8TLR7HPGDMAPK1 | |
| SCHEMBL24006376 | 0.86 | TLR8 (0.45) | TLR8TLR7HPGDMAPK1ALDH1A1 | |
| SCHEMBL10325458 | 0.86 | TLR8 (0.66) | TLR8TLR7HPGDMAPK1ABL1 | |
| SCHEMBL20646538 | 0.85 | TLR8 (0.61) | TLR8TLR7HPGDMAPK1 | |
| SCHEMBL19114852 | 0.82 | TLR8 (0.45) | TLR8TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240016813-A1 | METHODS OF TREATING SYMPTOMS OF CORONAVIRUS INFECTION | Accencio LLC | 2024-01-18 | — | — | US | disclosed |
| US-20240016813-A1 | METHODS OF TREATING SYMPTOMS OF CORONAVIRUS INFECTION | Accencio LLC | 2024-01-18 | — | — | US | disclosed |
| US-11702476-B2 | Anti-EGFR combinations for treating tumors | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2023-07-18 | — | — | US | disclosed |
| US-11702476-B2 | Anti-EGFR combinations for treating tumors | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2023-07-18 | — | — | US | disclosed |
| EP-3166640-B1 | COMBINATION THERAPY COMPOSITIONS AND METHODS FOR TREATING CANCERS | BIRDIE BIOPHARMACEUTICALS INC (KY) | 2023-06-14 | — | — | EP | disclosed |
| US-20220251212-A1 | ANTI-PD-L1 COMBINATIONS FOR TREATING TUMORS | BIRDIE BIOPHARMACEUTICALS INC (KY) | 2022-08-11 | — | — | US | disclosed |
| US-20220204641-A1 | ANTI-CD20 COMBINATIONS FOR TREATING TUMORS | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2022-06-30 | — | — | US | disclosed |
| US-20220175762-A1 | IMMUNE MODULATORY COMPOSITIONS AND METHODS FOR TREATING CANCERS | BIRDIE BIOPHARMACEUTICALS INC (KY) | 2022-06-09 | — | — | US | disclosed |
| EP-4001311-A1 | ANTI-PD-L1 COMBINATIONS FOR TREATING TUMORS | Birdie Biopharmaceuticals Inc. (KY) | 2022-05-25 | — | — | EP | disclosed |
| EP-3166976-B1 | ANTI-PD-L1 COMBINATIONS FOR TREATING TUMORS | BIRDIE BIOPHARMACEUTICALS INC (KY) | 2022-02-23 | — | — | EP | disclosed |
| WO-2016004875-A1 | COMBINATION THERAPY COMPOSITIONS AND METHODS FOR TREATING CANCERS | SHANGHAI BIRDIE BIOTECH, INC. (CN) | 2016-01-14 | — | — | WO | disclosed |
| WO-2016004876-A1 | ANTI-PD-L1 COMBINATIONS FOR TREATING TUMORS | SHANGHAI BIRDIE BIOTECH, INC. (CN) | 2016-01-14 | — | — | WO | disclosed |
| US-20140088085-A1 | Substituted Benzoazepines As Toll-Like Receptor Modulators | ARRAY BIOPHARMA, INC (US) | 2014-03-27 | — | — | US | disclosed |
| US-20140088085-A1 | Substituted Benzoazepines As Toll-Like Receptor Modulators | ARRAY BIOPHARMA, INC (US) | 2014-03-27 | — | — | US | disclosed |
| US-20140066432-A1 | Substituted Benzoazepines As Toll-Like Receptor Modulators | VENTIRX PHARMACEUTICALS, INC. | 2014-03-06 | — | — | US | disclosed |
| US-20140066432-A1 | Substituted Benzoazepines As Toll-Like Receptor Modulators | VENTIRX PHARMACEUTICALS, INC. | 2014-03-06 | — | — | US | disclosed |
| US-20140066432-A1 | Substituted Benzoazepines As Toll-Like Receptor Modulators | VENTIRX PHARMACEUTICALS, INC. | 2014-03-06 | — | — | US | disclosed |
| CN-103562186-A | Substituted benzazepines as modulators of TOLL-like receptors | VENTIRX PHARMACEUTICALS INC | 2014-02-05 | — | — | CN | disclosed |
| WO-2012097177-A2 | SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS | VENTIRX PHARMACEUTICALS, INC. (US) | 2012-07-19 | — | — | WO | disclosed |
| WO-2012097173-A2 | SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS | VENTIRX PHARMACEUTICALS, INC. (US) | 2012-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11702476-B2 | Anti-EGFR combinations for treating tumors | EGFR, ERBB3, ERBB2 | TLR8 1153/4885TLR7 2007/4885HPGD 3230/4885 |
| US-20140066432-A1 | Substituted Benzoazepines As Toll-Like Receptor Modulators | TLR8, TLR9, TLR1 | TLR8 1/4885TLR7 4/4885HPGD 3969/4885 |
| US-20220175762-A1 | IMMUNE MODULATORY COMPOSITIONS AND METHODS FOR TREATING CANCERS | IFNG, CD47, CD74 | TLR8 61/4885TLR7 75/4885HPGD 823/4885 |
| US-20240016813-A1 | METHODS OF TREATING SYMPTOMS OF CORONAVIRUS INFECTION | ACE2, ACE, TMPRSS2 | TLR8 878/4885TLR7 1436/4885HPGD 794/4885 |
| US-20220204641-A1 | ANTI-CD20 COMBINATIONS FOR TREATING TUMORS | CD209, CD68, CD47 | TLR8 694/4885TLR7 1058/4885HPGD 3221/4885 |
| US-20220251212-A1 | ANTI-PD-L1 COMBINATIONS FOR TREATING TUMORS | PDCD1LG2, CD274, PDCD1 | TLR8 585/4885TLR7 879/4885HPGD 2327/4885 |
| US-20140088085-A1 | Substituted Benzoazepines As Toll-Like Receptor Modulators | TLR8, TLR9, TLR1 | TLR8 1/4885TLR7 4/4885HPGD 3969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.